{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:41:37Z","timestamp":1789688497686,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ejca.2022.03.004","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T18:04:22Z","timestamp":1651255462000},"page":"108-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0278","authenticated-orcid":false,"given":"Norikazu","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Mukohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yasojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kokoro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Harano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-2246","authenticated-orcid":false,"given":"Maki","family":"Tanioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-6591","authenticated-orcid":false,"given":"Takahiro","family":"Kogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Semba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.03.004_bib1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3390\/cancers13040810","article-title":"Modulation of the vascular-immune environment in metastatic cancer","volume":"13","author":"He","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2022.03.004_bib2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13402-021-00602-3","article-title":"Angiogenesis as a hallmark of solid tumors - clinical perspectives","volume":"44","author":"Majidpoor","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.ejca.2022.03.004_bib3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41416-021-01330-z","article-title":"Vascular normalisation as the stepping stone into tumour microenvironment transformation","volume":"125","author":"Magnussen","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.03.004_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/jpm11020124","article-title":"Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect","volume":"11","author":"Huang","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.ejca.2022.03.004_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/jpm11030229","article-title":"The 35th anniversary of the discovery of EPR effect: a new wave of nanomedicines for tumor-targeted drug delivery-personal remarks and future prospects","volume":"11","author":"Maeda","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.ejca.2022.03.004_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.addr.2021.03.018","article-title":"The past, present, and future of breast cancer models for nanomedicine development","volume":"173","author":"Boix-Montesinos","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ejca.2022.03.004_bib7","doi-asserted-by":"crossref","first-page":"623760","DOI":"10.3389\/fonc.2021.623760","article-title":"Triggered drug release from liposomes: exploiting the outer and inner tumor environment","volume":"11","author":"Franco","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.03.004_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/pharmaceutics12060533","article-title":"Molecular simulations of PEGylated biomolecules, liposomes, and nanoparticles for drug delivery applications","volume":"12","author":"Lee","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejca.2022.03.004_bib9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/pharmaceutics13040520","article-title":"Advances in lipid-based nanoparticles for cancer chemoimmunotherapy","volume":"13","author":"Wang","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejca.2022.03.004_bib10","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1111\/cas.13392","article-title":"Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models","volume":"108","author":"Ito","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2022.03.004_bib11","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2022.03.004_bib12","series-title":"HALAVEN 0.44 mg\/ml solution for injection [summary of product characteristics]","year":"2021"},{"key":"10.1016\/j.ejca.2022.03.004_bib13","series-title":"Halaven (eribulin mesylate) [package insert]","year":"2021"},{"key":"10.1016\/j.ejca.2022.03.004_bib14","series-title":"Halaven (eribulin mesylate) [package insert]","year":"2020"},{"key":"10.1016\/j.ejca.2022.03.004_bib15","series-title":"Anticancer agent Halaven\u00ae approved for treatment of locally advanced or metastatic breast cancer in China","year":"2019"},{"key":"10.1016\/j.ejca.2022.03.004_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2013.01.010","article-title":"Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice","volume":"443","author":"Yu","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejca.2022.03.004_bib17","article-title":"Characterization of the liposomal formulation of eribulin mesylate (E7389) in mice [abstract]","volume":"vol. 75 (15 Suppl)","author":"Asano","year":"2015"},{"key":"10.1016\/j.ejca.2022.03.004_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41416-019-0377-x","article-title":"Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours","volume":"120","author":"Evans","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.03.004_bib19","doi-asserted-by":"crossref","unstructured":"Yamamoto N, Sato J, Koyama T, Iwasa S, Shimomura A, Kondo S, et\u00a0al. Phase 1 study of the liposomal formulation of eribulin (E7389-LF) in patients with advanced solid tumors: primary results of the dose-escalation part. Presented at: European Society of Medical Oncology; September 27\u2013October 1, 2019; Barcelona, Spain. Poster No. 348P.","DOI":"10.1093\/annonc\/mdz242.043"},{"key":"10.1016\/j.ejca.2022.03.004_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2022.03.004_bib21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.03.004_bib22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.004_bib23","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdr444","article-title":"A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer","volume":"23","author":"Aogi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.03.004_bib24","series-title":"Neulasta (pegfilgrastim) [prescribing information]","year":"2021"},{"key":"10.1016\/j.ejca.2022.03.004_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12282-017-0826-4","article-title":"Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine","volume":"25","author":"Pivot","year":"2018","journal-title":"Breast Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:48Z","timestamp":1760733348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922001447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":25,"alternative-id":["S0959804922001447"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}